Celldex Therapeutics, Inc. (CLDX) stock

CLDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30

$28.83+0.30 (+1.05%)

Close on Nov 13, 2026Market cap $2.26BP/E –Yield –

Celldex Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

For fiscal 2025 it was 87.1%, against 97.2% the year before. The highest annual figure on record is 97.8% in fiscal 2021.

Period	Period end	Value	Change (pts)
FY2025	Dec 31, 2025	87.1%	−10.1
FY2024	Dec 31, 2024	97.2%	+1.5
FY2023	Dec 31, 2023	95.6%	−0.1
FY2022	Dec 31, 2022	95.8%	−2.1
FY2021	Dec 31, 2021	97.8%	+0.5
FY2020	Dec 31, 2020	97.3%	+0.1
FY2019	Dec 31, 2019	97.2%	+4.5
FY2018	Dec 31, 2018	92.7%	−1.8
FY2017	Dec 31, 2017	94.5%	+18.1
FY2016	Dec 31, 2016	76.4%	–

Parsed from the XBRL in Celldex Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-15 reverse split on Feb 11, 2019
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CLDX.

Advertisement
300 × 250

See a number that looks wrong?